German researchers demonstrated that early treatment of trauma patients using recombinant factor VIIa reduced transfusions of red blood cells and fresh frozen plasma. The study, however, did not show that rFVIIa also reduces mortality. Further studies are needed to pinpoint the potential benefits of rFVIIa to selected groups of patients, the lead researcher said.

Full Story:
Doctor's Guide

Related Summaries